PFI slaps legal notice on Times Now over ‘baseless allegations’

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

New Delhi, Feb 4: The investigation into the incident of violence at Jamia Millia Islamia during an anti-citizenship law protest was at a crucial stage, the Centre told the Delhi High Court on Tuesday.

The submission before a bench of Chief Justice D N Patel and Justice C Hari Shankar was made by Solicitor General Tushar Mehta while seeking more time to file a report regarding the probe.

Taking note of the submission, the bench granted the Centre time till April 29 to file a reply.

During the hearing, senior advocate Colin Gonsalves, appearing for some students of Jamia, said 93 students and teachers filed complaints about alleged attacks on them by police but no FIR has been filed against the agency till date.

The other lawyers for the petitioners alleged that the government has not complied with the court order to file a response within four weeks of the last date of hearing on December 19.

The bench, however, declined to pass any interim order and granted time till April 29 to the government to file a reply.

New Delhi, May 13: With an increase of 3,525 COVID-19 cases reported in the last 24 hours, India's tally of positive coronavirus cases rises to 74,281 cases, as of Wednesday, said the Ministry of Health and Family Welfare.

The tally is inclusive of 47,480 patients who are active coronavirus cases and 24,385 patients who have been cured/discharged and one patient migrated.

With an increase of 122 deaths due to COVID-19 reported in the last 24 hours, the number of deaths in the country now stands at 2,415.

According to the ministry, Maharashtra has the most number of positive COVID-19 cases with 24,427 positive cases that include 5,125 patients recovered and 921 fatalities.

Gujarat has reported 8,903 COVID-19 cases inclusive of 3,246 recovered patients and 537 deaths due to the coronavirus.

Tamil Nadu reported 8,718 positive coronavirus cases with 2,134 patients recovering from the disease and 61 succumbing to the infection.

Delhi's tally of COVID-19 cases stands at 7,639 cases with 2,512 patients recovering and 86 patients died due to coronavirus.

Meanwhile Arunachal Pradesh (one case reported--now recovered), Goa (seven cases reported--all seven recovered), Manipur (two cases reported--both recovered) and Mizoram (one case reported--now recovered) have reported no new cases of COVID-19.